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Background: Vitamin D insufficiency correlates with mortality risk among patients with chronic kidney disease
(CKD). The survival benefits of active vitamin D treatment have been assessed in patients with CKD not requiring
dialysis and in patients with end stage renal disease (ESRD) requiring dialysis.
Methods: MEDLINE, Embase, the Cochrance Library, and article reference lists were searched for relevant
observational trials. The quality of the studies was evaluated using the Newcastle-Ottawa Scale (NOS) checklist.
Pooled effects were calculated as hazard ratios (HR) using random-effects models.
Results: Twenty studies (11 prospective cohorts, 6 historical cohorts and 3 retrospective cohorts) were included in
the meta-analysis., Participants receiving vitamin D had lower mortality compared to those with no treatment
(adjusted case mixed baseline model: HR, 0.74; 95% confidence interval [95% CI], 0.67-0.82; P <0.001; time-
dependent Cox model: HR, 0.71; 95% CI, 0.57-0.89; P <0.001). Participants that received calcitriol (HR, 0.63; 95% CI,
0.50-0.79; P <0.001) and paricalcitol (HR, 0.43 95% CI, 0.29-0.63; P <0.001) had a lower cardiovascular mortality. Patients
receiving paricalcitol had a survival advantage over those that received calcitriol (HR, 0.95; 95% CI, 0.91-0.99; P <0.001).
Conclusions: Vitamin D treatment was associated with decreased risk of all-cause and cardiovascular mortality in
patients with CKD not requiring dialysis and patients with end stage renal disease (ESRD) requiring dialysis. There was a
slight difference in survival depending on the type of vitamin D analogue. Well-designed randomized controlled trials
are necessary to assess the survival benefits of vitamin D.
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Mineral and bone disorders (MBD) are early and common
complications of CKD, and progress as glomerular filtration
rate (GFR) declines. Multiple factors contribute to the de-
velopment and maintenance of CKD-MBD, but principally
involve phosphate retention and vitamin D metabolism
abnormalities. Kidney Disease: Improving Global Outcomes
defines chronic kidney disease-mineral and bone disorder
(CKD-MBD) as a systemic syndrome characterized by ab-
normalities in serum calcium, phosphorus and parathyroid
hormone (PTH) concentration, vitamin D metabolism, and
bone turnover [1]. This syndrome is common among CKD* Correspondence: linshan@medmail.com.cn
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reproduction in any medium, provided the orpatients and has been associated with an increased risk of
cardiovascular calcification [2,3] and mortality [4]. The
Third National Health and Nutrition Examination Survey
(NHANES III) reported 15068 adults patients with vitamin
D deficiency and demonstrated a higher prevalence of
cardiovascular disease and mortality in untreated patients
[5]. An association between vitamin D deficiency and other
traditional cardiovascular risk factors, such as hypertension,
insulin resistance, diabetes, and dyslipidemia, has also been
reported [6,7]. The recognition of biochemical components
of CKD-MBD associated with increased mortality in
dialysis patients [8] and in patients with CKD not treated
with dialysis [9] has provided an impetus to explore the
effect of these factors on survival and associated treatment
modalities. Numerous reports have characterized the
nonskeletal benefits of vitamin D [10].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2369/14/199Wang et al. and Pittas et al. reported the benefits of
vitamin D supplementation on cardiovascular disease
(CVD) in the general population [11,12]. Nutritional
vitamin D supplementation has also been reported to be
beneficial to CKD patients [13]. Most reviews, however,
had few participants, short follow-up, and lacked survival
analyses. We conducted a systematic review of the literature
to assess whether vitamin D supplements reduced mortality
in patients with ESRD on dialysis and patients with CKD
not requiring dialysis.Methods
Data sources and Search strategy
MEDLINE (1966 to March 2013), EMBASE (1980 to
March 2013) and the Cochrance Controlled Trials Register
(CCTR-Specialized Renal Registry) were searched. Relevant
studies were identified [14,15]. References from identified
studies were reviewed to find additional relevant studies.
This systematic review was planned, conducted, and
reported following the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) guidelines [16].Eligibility criteria
Studies were included in the meta-analysis if they met the
following criteria: (1) cohort study design and follow-up
duration was at least 1 year; (2) patients had chronic
kidney disease or renal replacement treatment; (3) patients
were treated with active vitamin D sterols (alfacalcidol,
doxercalciferol, calcitriol, maxacalcitol, falecalcitriol and
paricalcitol), but not native vitamin D (ergocalciferol and
cholecalciferol); (4) the outcome of interest was all-cause
mortality or cardiovascular mortality; (5) there was quanti-
tative data (i.e., events rates, risk ratio [RR] or hazard ratio
[HR]). If data were duplicated in more than 1 study, we
included the study with the largest number of patients.Data extraction
All data were independently abstracted by 2 investigators
(Z.F.Z. and H.L.S) using a standardized data collection
form. Discrepancies were resolved through discussion with
other investigators (D.L. and J.Y.J.) and through reference
to the original articles.Figure 1 Selection process for studies included in the meta-analysis.Quality assessment
Two authors (Z.F.Z. and H.L.S.) independently evaluated
the quality of each study using the 9-star Newcastle-Ottawa
Scale (NOS) [17]. The Strengthening the Reporting of Ob-
servational Studies in Epidemiology (STROBE) checklist for
cohort studies was used to limit heterogeneity resulting
from differences in study design [18]. Disagreements were
resolved by consensus.Statistical analysis
Studies that provided relative risk (RR) or hazard ratios
(HR) were used directly in the pooled meta-analysis calcu-
lations. Overall crude (unadjusted) HR and adjusted HR
were calculated. Adjusted variables included demographic
and clinical values, biochemical indices and erythropoietin
and phosphate binder use. The overall pooled-effect esti-
mates were calculated using DerSimonian & Laird random-
effect models. The Q test was used to assess the presence
of heterogeneity and the I2 index was used to quantify
the extent of heterogeneity [19,20]. I2 values of 25% or
less indicated low heterogeneity, values near 50% indi-
cated moderate heterogeneity, and values 75% or greater
indicated high heterogeneity [21]. Publication bias was
assessed using funnel plots for each outcome and ln
Table 1 Observational studies examining active vitamin D administration in patients with CKD or on dialysis
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http://www.biomedcentral.com/1471-2369/14/199(HR) was plotted against its standard error. The Begg rank
correlation test was used to examine asymmetry of the
funnel plot [22]. The Egger weighted linear regression test
was used to examine the association between mean effect
estimate and its variance [23]. If an asymmetric funnelFigure 2 Pooled crude hazard ratio of all-cause mortality for vitamin
model; (B) time-dependent Cox model.plot was found, a contour-enhanced funnel plot was used
to further explore the source of bias [24]. P<0.05 was
considered statistically significant. All tests were 2-sided.
All analyses were conducted using STATA version 12.0
(StataCorp, College Station, Texas).D treatment vs. no treatment in CKD patients. (A) baseline Cox
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Literature search
Our initial literature search yielded 2483 citations. 2319
articles were excluded. The majority of these citations were
excluded at the level of title or abstract review. There wereFigure 3 Pooled case mixed adjusted hazard ratio of all-cause mortal
baseline Cox model; (B) time-dependent Cox model.164 citations which were considered to be potentially
eligible. 144 articles were excluded after reviewing the
article. Excluded articles included 37 narrative reviews, 31
duplication studies, 23 without vitamin D treatment, 20
without survival outcome, 15 without survival outcomeity for vitamin D treatment vs. no treatment in CKD patients. (A)
Table 2 Pooled hazard ratio for ESRD on dialysis and CKD not on dialysis
Patient group # patients Hazard ratio # studies I2, %
Patients with CKD not on dialysis
Crude all-cause mortality 2603 0.61 (0.48–0.77) 3 29.2
Adjusted all-cause mortality 2603 0.59 (0.35–0.99) 3 79
Patients with ESRD on dialysis
Crude all-cause mortality 109628 0.65 (0.58–0.73) 11 95
Adjusted all-cause mortality 66639 0.80 (0.68–0.94) 6 94.4
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http://www.biomedcentral.com/1471-2369/14/199data, 9 systematic reviews or meta-analyses, 5 author
replies, 2 comments, 2 editorials and 1 letter. Twenty
studies were considered eligible to be included in the
meta-analysis [25-44]. The overall search flow is presented
in Figure 1.
Study characteristics
The characteristics of eligible studies are summarized in
Table 1. Of the 20 included observational studies, eleven
were prospective cohort studies. [26,28,31,34-36,39,41-44].
The remaining 9 consisted of 6 historical cohort studies
[25,27,29,30,32,33] and 3 retrospective cohort studies
[37,38,40]. Seventeen studies reported ESRD patients on
dialysis [25-30,32,33,35-39,41-44] and three reported CKD
patients not on dialysis [31,34,40]. Five studies compared
calcitriol to no active vitamin D treatment [28,31,34,38,42],
two studies compared paricalcitol to no active vitamin D
treatment [33,42] and four studies compared alfacalcidol to
no active vitamin D treatment [26,40,41,44]. Nine studies
did not report the specific analogues used and com-
pared active vitamin D compounds with no treatment
[27,29,30,32,35-37,39,43]. Two studies compared the sur-
vival benefits of paricalcitol and calcitriol [25,30]. Several
sophisticated statistical models were used in these observa-
tional studies. Fifteen studies used a fixed covariate base-
line Cox model [25,26,30-35,37-41,43,44], two studies used
a time-dependent Cox model [27,42], and three studiesTable 3 Pooled hazard ratio for cardiovascular mortality in pa
Patient groups # pa
Crude cardiovascular mortality using baseline Cox model
Alfacalcitol vs no treatment 432
Calcitrol vs no treatment 1889
Paricalcitol vs no treatment 1230
Overall 3551
Adjusted cardiovascular mortality using baseline Cox model
Any vitamin D vs no treatment 466
Alfacalcitol vs no treatment 665
Calcitrol vs no treatment 1889
Paricalcitol vs no treatment 1230
Overall 4250used both Cox models [28,29,36]. Only 4 studies were
confirmed by intention to treat (ITT) analysis [27,30,32,34].
Vitamin D and all-cause mortality
14 studies examined the association between active vitamin
D treatment and crude all-cause mortality. Patients that re-
ceived alfacalcidol had a 46% (HR, 0.54; 95% CI, 0.37-0.80)
lower overall mortality risk compared to untreated patients.
Calcitriol, paricalcitol and not otherwise specified active
vitamin D treated patients had a 43% (HR, 0.57; 95% CI,
0.46-0.70), 27% (HR, 0.73; 95% CI, 0.62-0.87) and 36%
(HR, 0.64; 95% CI, 0.57-0.72) lower overall mortality
risk. Similar results were observed with the crude time-
dependent Cox model. All-cause mortality risk with
calcitriol, paricalcitol and not otherwise specified active
vitamin D was 26% (HR, 0.74; 95% CI, 0.55-0.99), 39%
(HR, 0.61; 95% CI, 0.58-0.64) and 30% (HR, 70; 95% CI,
0.63-0.79) lower, respectively, than that found patients
without active vitamin D treatment (Figure 2).
Ten studies reported vitamin D intake and risk for
all-cause mortality using an adjusted case mixed baseline
model. The risk of all-cause mortality was reduced 39%
(HR, 0.61; 95% CI, 0.50-0.73) with calcitriol and 14%
(HR, 0.86; 95% CI, 0.83-0.90) with paricalcitol. Using the
adjusted case mixed time-dependent Cox model, patients
who received active vitamin D treatment had a survival
benefit (HR, 0.71; 95% CI, 0.57-0.89) (Figure 3).tients receiving vitamin D or no treatment
tients Hazard ratio # studies I2, %
0.37 (0.25–0.55) 2 0
0.57 (0.46–0.71) 1 NA
0.31 (0.22–0.44) 1 NA
0.41 (0.28–0.59) 4 69.9
0.59 (0.19–1.82) 2 68.6
0.45 (0.14–1.47) 1 NA
0.63 (0.50–0.79) 1 NA
0.43 (0.29–0.63) 1 NA
0.59 (0.41–0.86) 5 83.6
Table 4 Comparison of all-cause mortality with paricaltitol and calcitrol
Patient group # patients Hazard ratio # studies I2, %
Crude baseline Cox model 75130 0.80 (0.75–0.86) 2 0
Adjusted baseline Cox case mixed model 16008 0.89 (0.79–1.00) 3 62.9
Adjusted baseline Cox case mixed and MICS model 14384 0.95 (0.91–0.99) 2 0
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CKD not on dialysis patients. Three studies evaluated
patients with CKD that were not on dialysis. The survival
advantage was similar in both the crude model (HR, 0.61;
95% CI, 0.43-0.77) and the adjusted model (HR, 0.59;
95% CI, 0.35-0.99). Patients with ESRD on dialysis had
less survival benefit in the adjusted model (HR, 0.80;
95% CI, 0.63-0.94) than in the crude model (HR, 0.65;
95% CI, 0.58-0.73) (Table 2).Vitamin D and cardiovascular mortality
Four studies reported the HR between active vitamin D
treatment and cardiovascular mortality using a crude
Cox model and five using an adjusted baseline Cox
model. A significant survival advantage was found in
patients receiving active vitamin D using an unadjusted
analysis (HR, 0.41; 95% CI, 0.28-0.59) and an adjusted ana-
lysis (HR, 0.59; 95% CI, 0.41-0.86). Similar results were
found with calcitriol and paricalcitol. The adjusted
baseline Cox model analysis found the reduction of
cardiovascular mortality with calcitriol and paricalcitol
to be 37% (HR, 0.63; 95% CI, 0.50-0.79) and 57% (HR,
0.43; 95% CI, 0.29-0.63), respectively. There was no sur-
vival difference associated with alfacalcidol treatment (HR,
0.45; 95% CI, 0.14-1.47) (Table 3).Table 5 Vitamin D dosage and all-cause mortality risk





Naves-Diaz et al. 1304 54 <1.75
Naves-Diaz et al. 1053 54 1.75-
Naves-Diaz et al. 432 54 3.5-7
Naves-Diaz et al. 184 54 >7.0
Paricalcitol
Kalantar-Zadeh et al. 5288 24 1.0-5
Kalantar-Zadeh et al. 11965 24 5.0-1
Kalantar-Zadeh et al. 8326 24 10.0-
Kalantar-Zadeh et al. 11816 24 >15.0
Shinaberger et al. 9575 30 1.7-2
Shinaberger et al. 8277 30 4.6-2
Shinaberger et al. 5875 30 6.4-3Calcitriol vs paricalcitol and all-cause mortality
Three studies reported hazard ratios that compared
calcitriol and paricalcitol treatment. The crude baseline
Cox model found a survival advantage with paricalcitol
treatment (HR, 0.80; 95% CI, 0.75-0.86). In contrast, the
adjusted baseline Cox case mixed and malnutrition-inflam-
mation-cachexia syndrome (MICS) model demonstrated
a survival advantage with calcitriol treatment (HR, 0.95;
95% CI, 0.91-0.99) in (Table 4).Vitamin D dosage and all-cause mortality
Three studies reported the relationship between active
vitamin D dose and all-cause mortality. Calcitriol treat-
ment was associated with a dose dependent decrease in
all-cause mortality. There was no survival advantage
when calcitriol dose exceeded 7 ug per week. A dose
dependent response was not found with paricalcitol
(Table 5).Assessment bias and meta-regression analysis
A publication bias was identified using an Egger regression
asymmetry test (β=−3.81, P=0.01) and a funnel plot
(Figure 4). A contour-enhanced funnel plot was used to
explore the source of the bias. The contour-enhanced




Hazard ratio 95% CI
1.05 0.46 0.37–0.53
3.5 2.38 0.58 0.49–0.70
.0 4.69 0.64 0.50–0.83
11.83 0.83 0.58–1.19
.0 NA 0.53 0.50–0.57
0.0 NA 0.54 0.51–0.57
15.0 NA 0.54 0.51–0.57
NA 0.73 0.69–0.77
0.1 10.9 0.93 0.89–0.97
5.8 15.2 0.88 0.84–0.94
0.8 18.6 0.88 0.84–0.93
Figure 4 Funnel plot and contour-enhanced funnel plot used to explore the source of publication bias. (A) funnel plot;
(B) contour-enhanced funnel plot.
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bias was a less likely cause of the funnel plot asymmetry
(Figure 4).
Within study heterogeneity was evaluated using covar-
iate meta regression analysis. Of the seven covariates,
publication year (t=−2.19, P=0.049) and study participants
(t=2.52, P=0.027) had the greatest between study variance.
The proportion of within-study variance explained by
publication year and study participants was 24.14% and
36.20%, respectively (Figure 5).
Discussion
Active vitamin D compounds were associated with a
reduced risk of mortality in patients with ESRD on dialysis
and patients with CKD not requiring dialysis. Several
mechanisms may explain how vitamin D can modifyrisk for mortality. Vitamin D down regulates the renin-
angiotensin system [45], improves insulin secretion and
sensitivity [46], inhibits vascular smooth-muscle cell pro-
liferation [47], protects normal endothelial cell function
[48], modulates inflammatory processes [49], inhibits anti-
coagulant activity [50], and inhibits myocardial cell hyper-
trophy and proliferation [51]. These findings suggest
that vitamin D may decrease mortality through multiple
pathways. Although the actual mechanism of mortality
is unclear, patient death has been associated with vas-
cular calcifications, left-ventricular hypertrophy and left-
ventricular dysfunction. The multi-organ protective effects
of vitamin D may explain the lower mortality rate found
in these patients.
A fixed covariate baseline Cox model was used in the
majority of included studies. Only 5 studies used a time-
Figure 5 Meta-regression graph of hazard ratio for all-cause mortality in vitamin D treated vs. no treatment patients.
(A) meta-regression by publication year; (B) meta-regression by number of study patients.
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active vitamin D use and survival. Although a standard
baseline Cox proportional regression model is usually
used to analyze cohort studies, it may be inadequate to
evaluate active vitamin D treatments due to the presence
of time-dependent variation in outcome. Higher serum
calcium and phosphorus levels were consistently associ-
ated with increased risk of death [4,52]. Elevated serum
PTH levels have also been associated with increased
mortality [4,33]. The serum levels of calcium, phosphorus
and PTH are affected by vitamin D therapy. Serum
levels of calcium, phosphorus and PTH vary during the
course of vitamin D therapy and affect patient outcome.
These mineral metabolism indexes are recognized as
time-dependent confounders. Time-dependent confounderscannot be controlled by conventional survival analysis
methods [53]. Marginal structural modeling (MSM) can
control for time-dependent confounders affected by prior
treatment [54]. Under some conditions, the treatment es-
timate from a MSM can have the same causal interpret-
ation as an estimate from a randomized clinical trial
[55]. Only the Tentori et al. study reported detailed data
regarding the survival advantage of patients treated with
active vitamin D. The unadjusted baseline Cox model and
time-varying MSM models demonstrated a 16% and 22%,
respectively, reduction of all-cause mortality associated with
active vitamin D treatment. Most studies included in this
meta-analysis had some selection bias. For example, the
study of Teng et al. [27] had statistical differences in the
baseline characteristics of patient age, primary cause of
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parathyroid hormone and hemoglobin levels. Several stud-
ies included in the meta-analysis used sophisticated statis-
tical techniques, such as adjustment for time-dependent
confounders, propensity score-matching or marginal struc-
tural models, to mimic the design of randomized controlled
trials. Only the characteristics of patients that were treated
with vitamin D analogues were known to the researchers.
Any confounding factors would be controlled by these
statistical methods and the results would be comparable
to randomized controlled trials. The problem with the ob-
servational studies was that such knowledge was not avail-
able. The potential presence of unmeasured confounders
prevented any conclusions of causation, even when sophis-
ticated statistical methods were used. The survival advan-
tage associated with active vitamin D treatment occurred
in a dose-dependent manner. This phenomenon has been
supported by two studies [29,32]. There has been no well-
designed dose gradient study to test this hypothesis. Al-
though we do not have higher quality evidence to prove this
association, we believe that vitamin D will improve survival.
The meta-analysis detected slight differences in survival
associated with different analogues of active vitamin D.
The baseline case mixed and MICS Cox models detected
a 5% lower mortality with paricalcitol treatment than with
calcitriol treatment. This slight survival difference may
be explained by differential effects of calcitriol and its
analogue, paricalcitol on vascular calcification. In vitro
studies have demonstrated that calcitriol is a growth
factor for vascular smooth muscle cells, while the analogue,
paricalcitol, is not [56]. In vivo studies have shown that
vitamin D sterols have a differential effect on vascular
calcification. 1-α-hydroxy vitamin D (calcitriol) was asso-
ciated with greater vascular calcification than paricalcitol,
even though there was equivalent suppression of PTH in
these animal models [57]. Only two well-designed cohort
studies or randomized controlled trials, Teng et al. [25]
and Tentori et al. [30], have evaluated the mortality risk
associated with different active vitamin D analogues. Fur-
ther studies are needed to clarify the survival difference
before one vitamin D analogue is recommended over
another in clinical practice.
Three studies included in the meta-analysis reported
mortality risk associated with different mean daily or
weekly doses of vitamin D. In the Naves-Diaz et al. study,
the maximum reduction of mortality occurred when the
mean daily dose of oral calcitriol was less than 0.25 ug.
This survival benefit was lost as the mean daily calcitriol
dose was increased to more than 1.0 ug. This dose-
dependent benefit effect was also reported with paricalcitol.
Kalantar-Zadeh et al. reported patients treated with mean
weekly doses of 1.0 ug to 5.0 ug of paricalcitol. Mean
weekly doses of paricalcitol above 15.0 ug were associated
with an 18% reduction of mortality risk. A possibleexplanation is that low-dose vitamin D exerts weaker
anti-vascular calcification effects than higher doses in
CKD patients. High doses of vitamin D could be associ-
ated with adverse effects, such as hypercalcemia, that
would overwhelm its protective effects.
There were several limitations in our meta-analysis. First,
only a few of the included studies used a time-dependent
or marginal structural model to analyze the follow-up
data. The majority of studies had limited power to draw
a definitive conclusion on the effects of vitamin D supple-
ments on all-cause or cardiovascular mortality. Second,
there was high heterogeneity in the meta-analysis. Sample
size and publication year were the sources of heterogeneity.
Third, the possible sources of heterogeneity could not
be carefully examined. This included observational studies
of the use of recombinant erythropoietin to correct anemia
and studies of phosphorus binders to ameliorate hyper-
phosphatemia in patients with CKD that showed beneficial
effects on mortality, CVD outcome, and progression of renal
disease. Fourth, we did not seek to identify unpublished
studies and several studies were excluded because the
published data were not suitable for meta-analysis.
Conclusions
Active vitamin D compounds used to treat abnormal
calcium, phosphorus and PTH levels in patients with
either ESRD on dialysis or CKD not requiring dialysis.
Active vitamin D compound treatment was associated
with decreased all cause and cardiovascular mortality. Low
dose active vitamin D compounds were associated with
improved survival. Large, well designed randomized trials
of active vitamin D supplements with different doses are
needed to elucidate the role of vitamin D supplementation
in reducing mortality.
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